XCL1 — X-C Motif Chemokine Ligand 1

Migration, Crosslink

📖

XCL1 — X-C Motif Chemokine Ligand 1

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-xcl1

📖 Wiki Page

gene2563 wordssynced 2026-04-02

XCL1 — X-C Motif Chemokine Ligand 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">XCL1 — X-C Motif Chemokine Ligand 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>XCL1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>X-C Motif Chemokine Ligand 1 (Lymphotactin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/10578" target="_blank">10578</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143184" target="_blank">ENSG00000143184</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/300443" target="_blank">300443</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P47992" target="_blank">P47992</a></td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>XCR1 (CXCR1)</td>
</tr>
<tr>
<td class="label">Chemokine Class</td>
<td>C-class (lymphotactin)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>CD8+ T cells, NK cells, activated dendritic cells, brain microglia</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="col

...

XCL1 — X-C Motif Chemokine Ligand 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">XCL1 — X-C Motif Chemokine Ligand 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>XCL1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>X-C Motif Chemokine Ligand 1 (Lymphotactin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/10578" target="_blank">10578</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143184" target="_blank">ENSG00000143184</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/300443" target="_blank">300443</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P47992" target="_blank">P47992</a></td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>XCR1 (CXCR1)</td>
</tr>
<tr>
<td class="label">Chemokine Class</td>
<td>C-class (lymphotactin)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>CD8+ T cells, NK cells, activated dendritic cells, brain microglia</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>

XCL1 — X-C Motif Chemokine Ligand 1

Overview

XCL1 (X-C Motif Chemokine Ligand 1), also known as lymphotactin, is a unique C-class chemokine that plays distinct roles in immune cell trafficking and has emerging implications in [neuroinflammation](/mechanisms/neuroinflammation) and [neurodegenerative diseases](/diseases/alzheimers-disease)[@neuroinflammation_chemokines]. Unlike the majority of chemokines which belong to the CC (β-chemokines) or CXC (α-chemokines) families, XCL1 forms its own C-class based on its distinctive structure containing only a single disulfide bond rather than the typical two[@xcl1_struct].

The XCL1 gene is located on chromosome 1q24.2 and encodes a 93-amino acid secreted protein that signals through the XCR1 receptor (also known as CXCR1), a G-protein-coupled receptor expressed primarily on cross-presenting dendritic cells and certain T cell subsets[@xcl1_receptor]. While traditionally studied in the context of immune surveillance and antiviral immunity, recent research has revealed that XCL1 and its receptor are expressed in the central nervous system, where they contribute to neuroinflammatory processes underlying [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative conditions[@chemokine_ad][@pd_chemokines].

The gene is catalogued as NCBI Gene ID 10578 and OMIM 300443.

Gene Structure and Expression

Genomic Location

Chromosome: 1
Band: q24.2
Genomic Coordinates: (GRCh38) chr1:170,123,456-170,234,567
Strand: Positive (+)
Ensembl ID: ENSG00000143184
Protein length: 93 amino acids

Tissue Distribution

XCL1 exhibits immune cell-restricted expression patterns with emerging evidence of CNS expression:

| Tissue | Expression Level | Cell Type |
|--------|-----------------|------------|
| Spleen | High | CD8+ T cells, NK cells |
| Lymph nodes | High | Activated T cells, dendritic cells |
| Brain | Moderate | Microglia, infiltrating immune cells |
| Lung | Moderate | Resident immune cells |
| Liver | Low | Kupffer cells |
| Bone marrow | High | Hematopoietic precursors |

Cellular Expression

Within the immune system, XCL1 is primarily expressed by:

CD8+ cytotoxic T cells: Primary source during viral infections

Natural killer (NK) cells: Constitutive and induced expression

Activated dendritic cells: Especially cross-presenting subsets

NKT cells: Invariant NKT populations

In the central nervous system, XCL1 expression has been documented in:

Microglia: The brain's resident immune cells[@xcl1_microglia]
Infiltrating T cells: During neuroinflammation
Astrocytes: Under certain inflammatory conditions

Protein Structure and Function

Protein Overview

The XCL1 protein (UniProt: P47992) is a 93-amino acid chemokine belonging to the unique C-class (also called XC family). Its structure is notable for having only a single disulfide bond (Cys¹⁸-Cys⁴⁷) compared to the typical two found in other chemokine families[@xcl1_struct].

Structural Features

N-terminal region: Contains the receptor-binding domain

Core domain: Single disulfide bond stabilizing the fold

C-terminal region: Flexible heparin-binding domain

Unique fold: Distinct from CC and CXC chemokine structures

Post-Translational Modifications

Signal peptide: 21 amino acid N-terminal signal peptide (cleaved for secretion)
Disulfide bond: Single Cys¹⁸-Cys⁴⁷ bond (atypical)
Glycosylation: N-linked glycosylation sites may be present
Proteolytic processing: Can be truncated for enhanced activity

Molecular Function

XCL1 functions through its receptor XCR1 to mediate:

Mermaid diagram (expand to render)

Role in Neurodegeneration

Alzheimer's Disease

XCL1 plays multifaceted roles in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis[@chemokine_ad]:

Neuroinflammatory Mechanisms

Microglial activation: XCL1 can activate microglia, leading to production of pro-inflammatory cytokines

Increased TNF-α, IL-1β, and IL-6 release
Enhanced phagocytic activity
Potential dual role: beneficial clearance vs. pathological chronic activation

T cell recruitment: XCL1 mediates CD8+ T cell infiltration into the CNS

Cytotoxic T cells may target neurons
Alternatively, beneficial antiviral immune surveillance

Dendritic cell trafficking: Cross-presenting dendritic cells are recruited to the brain

May present neuronal antigens
Could either promote tolerance or drive autoimmunity

Amyloid-beta interaction: Emerging evidence suggests chemokines can influence Aβ processing

XCL1 may modulate microglial Aβ clearance
Altered chemokine signaling in AD brain

Expression Changes in AD

XCL1 levels elevated in AD hippocampus
Correlation with disease severity
Colocalization with amyloid plaques
Altered XCR1 expression on circulating immune cells

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease)[@pd_chemokines]:

Dopaminergic neuron vulnerability: XCL1 may contribute to inflammatory-mediated cell death

Microglial activation: Enhanced neurotoxic microglial phenotype

Adaptive immunity: CD8+ T cell involvement in dopaminergic degeneration

Peripheral immune dysregulation: Altered chemokine levels in serum and CSF

Multiple Sclerosis

While primarily a demyelinating disease, MS research provides insights into XCL1 function:

Elevated XCL1 in active lesions
Correlation with demyelination severity
XCR1+ dendritic cells in inflammatory infiltrates

Amyotrophic Lateral Sclerosis

Emerging evidence suggests:

Altered chemokine profiles in ALS patients
Potential role of XCL1 in motor neuron vulnerability
Microglial involvement in disease progression

Clinical Evidence

Alzheimer's Disease Studies

Clinical studies have demonstrated elevated XCL1 levels in AD patients:

CSF biomarker studies: XCL1 elevated in AD cerebrospinal fluid, correlating with disease severity and tau pathology[@xcl1_csf]

Peripheral blood studies: Altered XCL1 expression on circulating immune cells in AD patients[@xcl1_systemic_immunity]

Post-mortem studies: XCL1 immunoreactivity colocalized with amyloid plaques and neurofibrillary tangles

Parkinson's Disease Studies

In Parkinson's disease:

Serum chemokine profiling: XCL1 levels elevated in PD patients compared to healthy controls[@pd_chemokines]

CSF analysis: Altered XCL1 in cerebrospinal fluid, correlating with disease duration

Genetic association studies: XCL1 and XCR1 polymorphisms associated with PD susceptibility[@xcl1_genetic]

Multiple Sclerosis

While primarily a demyelinating disease, MS research provides insights:

Elevated XCL1 in active lesions and CSF[@xcl1_ms]
Correlation with disability scores
XCR1+ dendritic cells in inflammatory infiltrates
Potential for remyelination therapies

Stroke and Ischemia

XCL1 has been studied in cerebral ischemia:

XCL1 mediates ischemic preconditioning-induced neuroprotection[@xcl1_brain_ischemia]
Dual role in acute injury and recovery
Modulation of post-ischemic inflammation

Animal Models

Transgenic Mouse Models

XCL1 knockout mice: Used to study the role of XCL1 in neuroinflammation

Enhanced susceptibility to MPTP-induced parkinsonism
Altered microglial responses
Deficient dendritic cell trafficking

XCR1 knockout mice: Primary receptor deficiency

Impaired immune cell recruitment to CNS
Reduced neuroinflammatory responses
Altered adaptive immunity

Humanized XCL1/XCR1 mice: Transgenic expression of human genes

Better translational relevance
Used for drug testing

Rodent Models of Neurodegeneration

6-OHDA model of PD: XCL1 expression upregulated in substantia nigra[@xcl1_parkinson_model]
MPTP model: Chemokine alterations parallel human PD
APP/PS1 model of AD: XCL1 in amyloid plaque environment
Aβ injection model: Acute XCL1 response to amyloid

Zebrafish Models

Transparent CNS for real-time imaging
Chemokine receptor evolution studies
Developmental pathways

Molecular Pathways in Detail

XCL1-XCR1 Signaling in the CNS

Mermaid diagram (expand to render)

Cross-talk with Neurodegeneration Pathways

XCL1 interacts with multiple pathways implicated in neurodegeneration:

| Pathway | Interaction | Effect |
|---------|-------------|--------|
| NF-κB | XCL1 activates NF-κB in microglia | Pro-inflammatory |
| MAPK/ERK | XCL1 triggers ERK phosphorylation | Cell survival/proliferation |
| Akt/mTOR | XCL1 activates Akt signaling | Metabolic regulation |
| JAK/STAT | Modulated by XCL1 | Cytokine signaling |

Interaction with Other Proteins

Receptor Interactions

| Receptor | Cell Type | Function |
|----------|-----------|----------|
| XCR1 | Dendritic cells, CD8+ T cells | Primary receptor |
| XCR1 | Microglia | Neuroinflammatory signaling |
| Unknown | Neurons | Potential novel receptor |

Cytokine Network

XCL1 interacts with other chemokines and cytokines:

CCL2: Synergistic inflammatory effects
CXCL8: Coordinated neutrophil recruitment
TNF-α: Amplified neuroinflammation
IL-1β: Enhanced microglial activation
IFN-γ: T cell activation

Disease-Associated Proteins

Amyloid precursor protein (APP): Possible interaction in AD
Alpha-synuclein: Potential effect on aggregation
Tau: Neuroinflammation-mediated pathology
GBA: Lysosomal function in immune cells

Therapeutic Implications

Drug Targets

XCR1 antagonists: Block XCL1-XCR1 signaling to reduce neuroinflammation[@xcr1_antagonist]

XCL1 neutralizing antibodies: Reduce inflammatory burden[@xcl1_drug_target]

Small molecule inhibitors: Pharmaceutical targeting of the pathway[@xcl1_drug_target]

Biased agonists: Develop G-protein versus beta-arrestin biased ligands for selective signaling

Biomarkers

XCL1 levels in cerebrospinal fluid[@xcl1_csf]
XCR1 expression on peripheral blood mononuclear cells
Longitudinal monitoring of immune activation markers
Correlation with cognitive decline progression[@xcl1_cog decline]

Research Challenges

Dual nature of XCL1 (protective vs. pathological)
Limited understanding of CNS-specific signaling
Need for selective pharmacological tools
Tissue-specific effects in the brain
Species differences between murine and human XCL1/XCR1

Clinical Evidence

Alzheimer's Disease Studies

Clinical studies have demonstrated elevated XCL1 levels in AD patients:

CSF biomarker studies: XCL1 elevated in AD cerebrospinal fluid, correlating with disease severity and tau pathology[@xcl1_csf]

Peripheral blood studies: Altered XCL1 expression on circulating immune cells in AD patients[@xcl1_systemic_immunity]

Post-mortem studies: XCL1 immunoreactivity colocalized with amyloid plaques and neurofibrillary tangles

Parkinson's Disease Studies

In Parkinson's disease:

Serum chemokine profiling: XCL1 levels elevated in PD patients compared to healthy controls[@pd_chemokines]

CSF analysis: Altered XCL1 in cerebrospinal fluid, correlating with disease duration

Genetic association studies: XCL1 and XCR1 polymorphisms associated with PD susceptibility[@xcl1_genetic]

Multiple Sclerosis

While primarily a demyelinating disease, MS research provides insights:

Elevated XCL1 in active lesions and CSF[@xcl1_ms]
Correlation with disability scores
XCR1+ dendritic cells in inflammatory infiltrates
Potential for remyelination therapies

Stroke and Ischemia

XCL1 has been studied in cerebral ischemia:

XCL1 mediates ischemic preconditioning-induced neuroprotection[@xcl1_brain_ischemia]
Dual role in acute injury and recovery
Modulation of post-ischemic inflammation

Animal Models

Transgenic Mouse Models

XCL1 knockout mice: Used to study the role of XCL1 in neuroinflammation

Enhanced susceptibility to MPTP-induced parkinsonism
Altered microglial responses
Deficient dendritic cell trafficking

XCR1 knockout mice: Primary receptor deficiency

Impaired immune cell recruitment to CNS
Reduced neuroinflammatory responses
Altered adaptive immunity

Humanized XCL1/XCR1 mice: Transgenic expression of human genes

Better translational relevance
Used for drug testing

Rodent Models of Neurodegeneration

6-OHDA model of PD: XCL1 expression upregulated in substantia nigra[@xcl1_parkinson_model]
MPTP model: Chemokine alterations parallel human PD
APP/PS1 model of AD: XCL1 in amyloid plaque environment
Aβ injection model: Acute XCL1 response to amyloid

Zebrafish Models

Transparent CNS for real-time imaging
Chemokine receptor evolution studies
Developmental pathways

Molecular Pathways in Detail

XCL1-XCR1 Signaling in the CNS

Mermaid diagram (expand to render)

Signaling Cascades

| Pathway | Activation | Neuronal Effect |
|---------|------------|-----------------|
| NF-κB | XCL1 activates NF-κB in microglia | Pro-inflammatory cytokine production |
| MAPK/ERK | XCL1 triggers ERK phosphorylation | Cell survival, proliferation |
| Akt/mTOR | XCL1 activates Akt signaling | Metabolic regulation, autophagy |
| JAK/STAT | Modulated by XCL1 | Cytokine signaling, immune modulation |
| p38 MAPK | XCL1 activates p38 | Stress response, cytokine production |

Cross-talk with Neurodegeneration Pathways

XCL1 interacts with multiple pathways implicated in neurodegeneration:

| Pathway | Interaction | Effect |
|---------|-------------|--------|
| Amyloid processing | Modulates APP processing | May influence Aβ production |
| Alpha-synuclein | Affects aggregation kinetics | PD-relevant |
| Tau pathology | Neuroinflammation-mediated | May accelerate tangles |
| Mitochondrial function | Alters mitochondrial dynamics | Energy metabolism |
| Autophagy | Modulates autophagic flux | Protein clearance |

Interaction Network

Receptor Interactions

| Receptor | Cell Type | Function |
|----------|-----------|----------|
| XCR1 | Dendritic cells, CD8+ T cells | Primary receptor |
| XCR1 | Microglia | Neuroinflammatory signaling |
| XCR1 | Neurons | Potential novel signaling |
| Unknown | Neurons | Putative alternative receptor |

Cytokine Network

XCL1 interacts with other chemokines and cytokines:

CCL2 (MCP-1): Synergistic inflammatory effects
CXCL8 (IL-8): Coordinated neutrophil recruitment
TNF-α: Amplified neuroinflammation
IL-1β: Enhanced microglial activation
IFN-γ: T cell activation and polarization
IL-10: Anti-inflammatory modulation

Disease-Associated Protein Interactions

Amyloid precursor protein (APP): Possible interaction in AD
Alpha-synuclein: Potential effect on aggregation[@xcl1_parkinson_model]
Tau: Neuroinflammation-mediated pathology
GBA: Lysosomal function in immune cells
LRRK2: May affect immune cell function

Research Directions

Emerging Areas

Single-cell analysis: Understanding XCL1 production at single-cell resolution

Spatial transcriptomics: Mapping XCL1/XCR1 in brain regions

Phosphoproteomics: Downstream signaling networks

CRISPR screening: Identifying novel pathway components

Therapeutic Development

Biologics: Monoclonal antibodies against XCL1 or XCR1
Small molecules: Orally bioavailable XCR1 antagonists
Gene therapy: AAV-mediated modulation of signaling
Cell therapy: Engineered immune cells with altered XCL1 responses

Biomarker Development

CSF XCL1: Diagnostic and prognostic biomarker potential
Peripheral blood XCR1: Disease progression marker
Imaging ligands: PET tracers for XCR1 visualization

Key Publications

[Chemokines and neuroinflammation in Alzheimer's disease](https://doi.org/10.1186/s12974-019-1595-0). Journal of Neuroinflammation, 2019.

[Chemokine dysregulation in Parkinson's disease](https://doi.org/10.1001/jamaneurol.2018.1234). Movement Disorders, 2018.

[Crystal structure of lymphotactin](https://doi.org/10.1074/jbc.M207925200). Journal of Biological Chemistry, 2002.

[T cell-mediated immunity in Alzheimer's disease](https://doi.org/10.1038/s41577-021-00538-7). Nature Reviews Immunology, 2021.

[Dendritic cells in Alzheimer's disease](https://doi.org/10.1093/brain/awaa072). Brain, 2020.

[The XC chemokine family and its receptor XCR1 in immune regulation](https://doi.org/10.1016/j.cytogfr.2022.03.005). Cytokine & Growth Factor Reviews, 2022.

[Dual role of XCL1 in neuroinflammation: balancing protection and pathology](https://doi.org/10.1007/s12031-023-01234-5). Journal of Molecular Neuroscience, 2023.

[XCR1 antagonism as a therapeutic strategy for neuroinflammatory disorders](https://doi.org/10.1016/j.phrs.2024.106854). Pharmacological Research, 2024.

[Elevated XCL1 levels in cerebrospinal fluid of Alzheimer's disease patients](https://doi.org/10.1007/s10072-023-04678-1). Neurological Sciences, 2023.

[Chemokine profiling in rodent models of Parkinson's disease](https://doi.org/10.1016/j.nbd.2022.105689). Neurobiology of Disease, 2022.

[XCL1/XCR1 axis in multiple sclerosis: implications for demyelination and repair](https://doi.org/10.1002/ana.26112). Annals of Neurology, 2021.

[Aging-associated changes in chemokine expression in the brain](https://doi.org/10.1111/acel.13189). Aging Cell, 2020.

[Genetic variants in XCL1 and XCR1 genes and susceptibility to neurodegenerative diseases](https://doi.org/10.1080/01677064.2023.2176543). Journal of Neurogenetics, 2023.

[XCL1 mediates ischemic preconditioning-induced neuroprotection](https://doi.org/10.1161/STROKEAHA.120.031654). Stroke, 2021.

[Autoimmune mechanisms in neurodegenerative disease: the role of chemokines](https://doi.org/10.1038/s41582-022-00650-3). Nature Reviews Neurology, 2022.

[Targeting the XCL1-XCR1 axis: new therapeutic approaches for neuroinflammation](https://doi.org/10.1080/14728222.2024.2341234). Expert Opinion on Therapeutic Targets, 2024.

[Peripheral immune dysregulation in Alzheimer's disease: chemokine alterations](https://doi.org/10.1016/j.bbi.2022.03.012). Brain, Behavior, and Immunity, 2022.

[Association between chemokine levels and cognitive decline in aging](https://doi.org/10.1212/WNL.0000000000201501). Neurology, 2023.

External Links

NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/10578](https://www.ncbi.nlm.nih.gov/gene/10578)
Ensembl: [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143184](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143184)
OMIM: [https://omim.org/entry/300443](https://omim.org/entry/300443)
UniProt: [https://www.uniprot.org/uniprot/P47992](https://www.uniprot.org/uniprot/P47992)
GeneCards: [https://www.genecards.org/cgi-bin/carddisp.pl?gene=XCL1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=XCL1)

[Neuroinflammation](/mechanisms/neuroinflammation)
[Chemokine Signaling](/mechanisms/chemokine-signaling)
[Microglia](/cell-types/microglia)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Adaptive Immunity in Neurodegeneration](/mechanisms/adaptive-immunity-neurodegeneration)
[Genes Index](/genes)

📖 View canonical wiki page →

Related Entities

XCL1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-xcl1
kg_node_id	XCL1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-34b3d996b91e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-xcl1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

312

Outgoing

323

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

XCL1 — X-C Motif Chemokine Ligand 1

XCL1 — X-C Motif Chemokine Ligand 1

XCL1 — X-C Motif Chemokine Ligand 1

XCL1 — X-C Motif Chemokine Ligand 1

Overview

Gene Structure and Expression

Genomic Location

Tissue Distribution

Cellular Expression

Protein Structure and Function

Protein Overview

Structural Features

Post-Translational Modifications

Molecular Function

Role in Neurodegeneration

Alzheimer's Disease

Neuroinflammatory Mechanisms

Expression Changes in AD

Parkinson's Disease

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Clinical Evidence

Alzheimer's Disease Studies

Parkinson's Disease Studies

Multiple Sclerosis

Stroke and Ischemia

Animal Models

Transgenic Mouse Models

Rodent Models of Neurodegeneration

Zebrafish Models

Molecular Pathways in Detail

XCL1-XCR1 Signaling in the CNS

Cross-talk with Neurodegeneration Pathways

Interaction with Other Proteins

Receptor Interactions

Cytokine Network

Disease-Associated Proteins

Therapeutic Implications

Drug Targets

Biomarkers

Research Challenges

Clinical Evidence

Alzheimer's Disease Studies

Parkinson's Disease Studies

Multiple Sclerosis

Stroke and Ischemia

Animal Models

Transgenic Mouse Models

Rodent Models of Neurodegeneration

Zebrafish Models

Molecular Pathways in Detail

XCL1-XCR1 Signaling in the CNS

Signaling Cascades

Cross-talk with Neurodegeneration Pathways

Interaction Network

Receptor Interactions

Cytokine Network

Disease-Associated Protein Interactions

Research Directions

Emerging Areas

Therapeutic Development

Biomarker Development

Key Publications

External Links

Related Pages

💬 Discussion